(NASDAQ:BIIB) Subcutaneous delivery increases accessibility and introduces potential for at-home administration, following model of diabetes and GLP-1 drugs NEW YORK, Aug. 29, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of...
Related Questions
How will the FDA approval of Leqembi's subcutaneous formulation influence Biogen's shortâterm stock price and volume dynamics?
What could be the revenue upside and market share impact for BIIB relative to existing AD therapies and emerging competitors?
How might this approval affect the outlook for combinationâtherapy pipelines and potential partnerships within the Alzheimer's treatment space?